DK1063995T3 - Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator - Google Patents

Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator

Info

Publication number
DK1063995T3
DK1063995T3 DK99916907T DK99916907T DK1063995T3 DK 1063995 T3 DK1063995 T3 DK 1063995T3 DK 99916907 T DK99916907 T DK 99916907T DK 99916907 T DK99916907 T DK 99916907T DK 1063995 T3 DK1063995 T3 DK 1063995T3
Authority
DK
Denmark
Prior art keywords
nmda receptor
receptor complex
opioid antagonist
combination
complex modulator
Prior art date
Application number
DK99916907T
Other languages
Danish (da)
English (en)
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Philippe Durbin
Original Assignee
Merck Sante Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante Sas filed Critical Merck Sante Sas
Application granted granted Critical
Publication of DK1063995T3 publication Critical patent/DK1063995T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99916907T 1998-03-26 1999-03-26 Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator DK1063995T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (de) 1998-03-26 1998-03-26 Pharmazeutische Zusammensetzung zur Behandlung von Alkohol- oder Drogenabhängigkeit, die Opioid Antagonisten mit NMDA-Rezeptorkomplex-Modulatoren enthält
PCT/EP1999/002337 WO1999048500A1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (1)

Publication Number Publication Date
DK1063995T3 true DK1063995T3 (da) 2003-03-10

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99916907T DK1063995T3 (da) 1998-03-26 1999-03-26 Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator

Country Status (17)

Country Link
US (1) US6512009B1 (de)
EP (2) EP0945133A1 (de)
KR (1) KR20010034678A (de)
AT (1) ATE230993T1 (de)
AU (1) AU758569B2 (de)
BR (1) BR9909138A (de)
CA (1) CA2325739C (de)
CZ (1) CZ296367B6 (de)
DE (1) DE69904922T2 (de)
DK (1) DK1063995T3 (de)
ES (1) ES2190205T3 (de)
HU (1) HU226555B1 (de)
NO (1) NO319313B1 (de)
PL (1) PL193241B1 (de)
RU (1) RU2226107C2 (de)
SK (1) SK284623B6 (de)
WO (1) WO1999048500A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
CA2336879C (en) * 1998-07-20 2010-06-01 Peptech Limited Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (de) * 2001-05-23 2002-12-18 Pfizer Products Inc. Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
CA2487577C (en) 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
EP1572164A2 (de) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Orale dosierungsformen enthaltend medikamentenkerne mit kontrollierter freisetzung und gelatinkapselbeschichtungen mit sofortfreisetzung
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
MXPA05012768A (es) * 2003-05-30 2006-02-22 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
JP2010513569A (ja) * 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
JP2011506319A (ja) * 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
MX2010009509A (es) 2008-02-28 2010-11-30 Univ Virginia Gen transportador de serotonina y tratamiento de alcoholismo.
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EA024450B1 (ru) 2010-07-02 2016-09-30 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход к лечению и диагностике алкогольной и наркотической зависимости
EP2751137A4 (de) 2011-09-09 2015-06-03 Univ Virginia Patent Found Molekularer genetischer ansatz zur behandlung und diagnose von alkohol- und drogenabhängigkeit
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
WO2023023038A1 (en) * 2021-08-17 2023-02-23 Yale University Treatment compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置

Also Published As

Publication number Publication date
CA2325739C (en) 2007-05-15
US6512009B1 (en) 2003-01-28
AU3522699A (en) 1999-10-18
BR9909138A (pt) 2000-12-05
DE69904922D1 (de) 2003-02-20
EP1063995A1 (de) 2001-01-03
HK1032542A1 (en) 2001-07-27
CA2325739A1 (en) 1999-09-30
SK14282000A3 (sk) 2001-05-10
HU226555B1 (en) 2009-03-30
DE69904922T2 (de) 2004-01-08
HUP0101546A2 (hu) 2001-09-28
NO319313B1 (no) 2005-07-11
RU2226107C2 (ru) 2004-03-27
SK284623B6 (sk) 2005-08-04
NO20004788L (no) 2000-11-24
ATE230993T1 (de) 2003-02-15
PL343069A1 (en) 2001-07-30
ES2190205T3 (es) 2003-07-16
EP1063995B1 (de) 2003-01-15
PL193241B1 (pl) 2007-01-31
HUP0101546A3 (en) 2002-10-28
WO1999048500A1 (en) 1999-09-30
CZ296367B6 (cs) 2006-02-15
AU758569B2 (en) 2003-03-27
NO20004788D0 (no) 2000-09-25
EP0945133A1 (de) 1999-09-29
KR20010034678A (ko) 2001-04-25
CZ20003525A3 (cs) 2001-04-11

Similar Documents

Publication Publication Date Title
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
DK0800519T3 (da) Steroidreceptormodulatorforbindelser og fremgangsmåder
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
NO20031266D0 (no) Kondenserte heterocykliske suksinimid-forbindelser og analoger derav, modulatorer for nukle¶r hormonreseptorfunksjon
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DK0812195T3 (da) Farmaceutisk sammensætning til piperidinoalkanolforbindelser
FI965203A7 (fi) Morfiinia, polypyrrolidonia ja polyalkyleenioksidia sisältävä koostumus
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
EA199900373A2 (ru) Фармацевтические композиции
ATE404211T1 (de) Xenon als nmda-antogonist zur neuroprotektion
DE60019334D1 (de) Antivirale arznei
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
DK0810883T3 (da) Konjugat indeholdende DTPA og albumin til individuel dosering af lægemidler
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
DK1150681T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende desoxypeganin til behandling af nikotinafhængighed
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
NO982562L (no) Sammensetning for behandling av smerte
SE0004827D0 (sv) Therapeutic compounds
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen